- Home
- VUZI vs PBYI Comparison
VUZI vs PBYI Comparison
Compare VUZI & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VUZI
- PBYI
- Stock Information
- Founded
- VUZI 1997
- PBYI 2010
- Country
- VUZI United States
- PBYI United States
- Employees
- VUZI N/A
- PBYI N/A
- Industry
- VUZI Industrial Machinery/Components
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- VUZI Technology
- PBYI Health Care
- Exchange
- VUZI Nasdaq
- PBYI Nasdaq
- Market Cap
- VUZI 207.4M
- PBYI 171.7M
- IPO Year
- VUZI N/A
- PBYI N/A
- Fundamental
- Price
- VUZI $2.00
- PBYI $4.85
- Analyst Decision
- VUZI Strong Buy
- PBYI Strong Buy
- Analyst Count
- VUZI 1
- PBYI 1
- Target Price
- VUZI $2.00
- PBYI $7.00
- AVG Volume (30 Days)
- VUZI 1.4M
- PBYI 559.4K
- Earning Date
- VUZI 08-14-2025
- PBYI 08-07-2025
- Dividend Yield
- VUZI N/A
- PBYI N/A
- EPS Growth
- VUZI N/A
- PBYI 434.29
- EPS
- VUZI N/A
- PBYI 0.97
- Revenue
- VUZI $5,331,630.00
- PBYI $238,062,000.00
- Revenue This Year
- VUZI $45.35
- PBYI N/A
- Revenue Next Year
- VUZI $54.01
- PBYI N/A
- P/E Ratio
- VUZI N/A
- PBYI $4.98
- Revenue Growth
- VUZI N/A
- PBYI 8.63
- 52 Week Low
- VUZI $0.83
- PBYI $2.23
- 52 Week High
- VUZI $5.79
- PBYI $5.05
- Technical
- Relative Strength Index (RSI)
- VUZI 37.73
- PBYI 83.47
- Support Level
- VUZI $1.88
- PBYI $3.05
- Resistance Level
- VUZI $2.34
- PBYI $3.41
- Average True Range (ATR)
- VUZI 0.14
- PBYI 0.26
- MACD
- VUZI 0.00
- PBYI 0.12
- Stochastic Oscillator
- VUZI 21.05
- PBYI 89.66
About VUZI Vuzix Corporation
Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.